Peter S Mortimer, Mark Pearson, Patryk Gawrysiak, Katie Riches, Vaughan Keeley, Kirstie F Tew, Ewan J Cranwell
{"title":"LymphActiv: A Digital Physical Activity Behavior Intervention for the Treatment of Lymphedema and Lipedema.","authors":"Peter S Mortimer, Mark Pearson, Patryk Gawrysiak, Katie Riches, Vaughan Keeley, Kirstie F Tew, Ewan J Cranwell","doi":"10.1089/lrb.2023.0033","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Lymphedema and lipedema are debilitating conditions with no proven drug or surgical therapy. Effective treatment requires self-management through movement and compression to reduce limb volume and the incidence of cellulitis. The addition of personalized everyday physical activity (PA) could be transformative, increasing the therapy window to include all waking hours per week and enabling an increased dose of PA. <b><i>Aim:</i></b> This service evaluation aimed to determine the feasibility of LymphActiv as a treatment option for lymphedema and lipedema patients. <b><i>Methods:</i></b> This service evaluation followed an open observational cohort design, including 55 patients who participated in LymphActiv over 24 weeks. Patients wore an objective PA monitor and interacted with their data in an online dashboard, alongside remote mentor support. Primary outcomes were changes to PA, body weight, limb volume and quality of life. Clinical assessments occurred at baseline and after the 24-week program. Noncompleters were used as a quasi-control group for comparison. <b><i>Results:</i></b> Thirty-seven patients completed, of which 81% improved PA. On average, completers reduced their right and left lower limb volumes by -1.8% and -2.1%, respectively. Completers also experienced small average weight losses of -1.2 kg. Noncompleters experienced small average increases in each of these outcome measures. <b><i>Discussion:</i></b> These results establish the value of LymphActiv, providing benefit to patients who might otherwise have deteriorated. For services, this could lead to substantial cost-savings through reduced admissions, greater patient independence, and less need for community health care input. The next step is to undertake a randomized, controlled trial comparing the intervention with standard care.</p>","PeriodicalId":18168,"journal":{"name":"Lymphatic research and biology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lymphatic research and biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/lrb.2023.0033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Lymphedema and lipedema are debilitating conditions with no proven drug or surgical therapy. Effective treatment requires self-management through movement and compression to reduce limb volume and the incidence of cellulitis. The addition of personalized everyday physical activity (PA) could be transformative, increasing the therapy window to include all waking hours per week and enabling an increased dose of PA. Aim: This service evaluation aimed to determine the feasibility of LymphActiv as a treatment option for lymphedema and lipedema patients. Methods: This service evaluation followed an open observational cohort design, including 55 patients who participated in LymphActiv over 24 weeks. Patients wore an objective PA monitor and interacted with their data in an online dashboard, alongside remote mentor support. Primary outcomes were changes to PA, body weight, limb volume and quality of life. Clinical assessments occurred at baseline and after the 24-week program. Noncompleters were used as a quasi-control group for comparison. Results: Thirty-seven patients completed, of which 81% improved PA. On average, completers reduced their right and left lower limb volumes by -1.8% and -2.1%, respectively. Completers also experienced small average weight losses of -1.2 kg. Noncompleters experienced small average increases in each of these outcome measures. Discussion: These results establish the value of LymphActiv, providing benefit to patients who might otherwise have deteriorated. For services, this could lead to substantial cost-savings through reduced admissions, greater patient independence, and less need for community health care input. The next step is to undertake a randomized, controlled trial comparing the intervention with standard care.
期刊介绍:
Lymphatic Research and Biology delivers the most current peer-reviewed advances and developments in lymphatic biology and pathology from the world’s leading biomedical investigators. The Journal provides original research from a broad range of investigative disciplines, including genetics, biochemistry and biophysics, cellular and molecular biology, physiology and pharmacology, anatomy, developmental biology, and pathology.
Lymphatic Research and Biology coverage includes:
-Vasculogenesis and angiogenesis
-Genetics of lymphatic disorders
-Human lymphatic disease, including lymphatic insufficiency and associated vascular anomalies
-Physiology of intestinal fluid and protein balance
-Immunosurveillance and immune cell trafficking
-Tumor biology and metastasis
-Pharmacology
-Lymphatic imaging
-Endothelial and smooth muscle cell biology
-Inflammation, infection, and autoimmune disease